Market revenue in 2022 | USD 14.5 million |
Market revenue in 2030 | USD 36.1 million |
Growth rate | 12.1% (CAGR from 2022 to 2030) |
Largest segment | 13-24 weeks |
Fastest growing segment | 0-12 weeks |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | 0-12 weeks, 13-24 weeks, 25-36 weeks |
Key market players worldwide | CooperSurgical, Natera Inc, Eurofins Scientific SE, Illumina Inc, Centogene NV Ordinary Shares, MedGenome, Myriad Genetics Inc, Roche Holding AG, Qiagen NV, Labcorp Holdings Inc, Quest Diagnostics Inc, Biora Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non invasive prenatal testing market will help companies and investors design strategic landscapes.
13-24 weeks was the largest segment with a revenue share of 52.41% in 2022. Horizon Databook has segmented the Argentina non invasive prenatal testing market based on 0-12 weeks, 13-24 weeks, 25-36 weeks covering the revenue growth of each sub-segment from 2018 to 2030.
Advanced technologies are anticipated to contribute to market growth. Increasing government R&D spending, the presence of skilled healthcare professionals, the increasing focus of multinational pharmaceutical companies on clinical diagnostics, and an increase in patient awareness levels are anticipated to fuel market development over the forecast period.
The rising prevalence of chronic diseases, combined with an aging population, is also driving the regional market. Furthermore, rising healthcare spending in this region's developing countries, as well as rising medical tourism, are driving market development.
Argentina & Brazil are two South American nations where non-invasive prenatal testing (NIPT) has recently been commercialized; however, the technology is not yet widespread. In the meantime, both countries have reproductive regulations that govern the use of abortion, which may limit the use and acceptance of NIPT.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina non invasive prenatal testing market , including forecasts for subscribers. This country databook contains high-level insights into Argentina non invasive prenatal testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account